Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.

Authors
  • Kawase, Miyuki
  • Shirato, Kazuya
  • van der Hoek, Lia
  • Taguchi, Fumihiro
  • Matsuyama, Shutoku
Type
Published Article
Journal
Journal of Virology
Publisher
American Society for Microbiology
Publication Date
Jun 01, 2012
Volume
86
Issue
12
Pages
6537–6545
Identifiers
DOI: 10.1128/JVI.00094-12
PMID: 22496216
Source
Medline
License
Unknown

Abstract

The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester], a cathepsin inhibitor, efficiently prevented both cell entry and the multistep growth of SARS-CoV in human Calu-3 airway epithelial cells. This efficient inhibition could be attributed to the dual blockade of entry from the cell surface and through the endosomal pathway. These observations suggest camostat as a candidate antiviral drug to prevent or depress TMPRSS2-dependent infection by SARS-CoV.

Report this publication

Statistics

Seen <100 times